Bi-specific digoxigenin binding antibodies

US9050375B2 · kind B2 · utility

Assignee

• Hoffmann-La Roche Inc. · US

Inventors

• Birgit Bramlage · Ebikon, CH
• Ulrich Brinkmann · Weilheim, DE
• Rebecca Croasdale · Antdorf, DE
• Simone Dill · Kulmbach, DE
• Wilma Dormeyer · Munich, DE
• Guy Georges · Habach, DE
• Michael Grote · Penzberg, DE
• Alexander Haas · Munich, DE
• Eike Hoffmann · Viernheim, DE
• Ludger Markus Ickenstein · Kulmbach, DE
• Kerstin Jahn-Hofmann · Neu-Isenburg, DE
• Matthias John · Hallstadt, DE
• Silke Metz · Annaberg-Buchholz, DE
• Olaf Mundigl · Weilheim, DE
• Werner Scheuer · Penzberg, DE
• Jan Olaf Stracke · Penzberg, DE

Key dates

• Filing date: Jun 30, 2010
• Grant date: Jun 9, 2015
• Expiry date: Jun 30, 2030

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12N2320/32
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

This invention relates to bispecific antibodies and antibody fragments against a target protein and a hapten, wherein the hapten is PEG or biotin, most preferably digoxigenin, methods for their production, their use as a delivery platform for therapeutic or diagnostic agents, pharmaceutical compositions containing said antibodies, and uses thereof.